PHARMACY

Kerr Drug completes chainwide implementation of PDX pharmacy system

BY Alaric DeArment

RALEIGH, N.C. — Kerr Drug has rolled out the PDX Enterprise Pharmacy System chainwide, the retail pharmacy chain said.

Kerr said the system would help it focus on "the future of pharmacy," with increased prescription volume and higher patient care requirements.

"We are really investing heavily in our infrastructure," Kerr Drug VP and CIO Joey Dorsett said. "As a regional chain, it hasn’t always been possible to be the first adopters of all the innovative technologies, but it is non-negotiable that we provide pharmacy services with the best of the best. With PDX, we are able to deliver cutting-edge solutions that improve patients’ lives through better technology."

The PDX system features integrated, centralized pharmacy records, improves work processes and efficiencies and helps to lower labor costs through separation of tasks by the pharmacists and technicians, Kerr said.

The company said the completion of the PDX platform alsowould complement its mobile pharmacy system, allowing smartphone users to refill prescriptions, receive pickup and dosage reminders and retrieve their prescription history via mobile.

"Kerr delivers cutting-edge solutions to improve our patients’ health and make their lives easier," Kerr president and CEO Tony Civello said. "The mobile option allows patients to convert their phones into medical wallets … to access a wide range of our pharmacy services."


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Three-quarters of Americans never receive skin exams, perform mole self checks, survey finds

BY Alaric DeArment

IRVINGTON, N.Y. — Less than one-quarter of American adults have ever had a skin check by a dermatologist despite rising rates of skin cancer, according to a new survey.

The survey, conducted online by Harris Interactive on behalf of Mela Sciences, a company that makes a device for use by doctors to detect potentially dangerous skin lesions, polled 2,109 American adults between Jan. 29 and 31, finding that only 23% of Americans perform monthly mole self-checks, while 37% think they are not at risk from skin cancer, despite industry statistics indicating that 1-in-5 will develop skin cancer annually. At the same time, while 85% stated correctly that moles are often precursors to melanoma, 20% said they "are simply beauty marks."

"While many forms of cancer are on the decline, melanoma continues to rise and, in fact, is the leading cause of cancer death in women ages 25 to 30 years and second only to breast cancer in women ages 30 to 34 years," Mela Sciences president and CEO Joseph Gulfo said. "We have a tremendous opportunity to spread awareness and change the course of the disease by advocating for the detection of melanoma at its most curable stage, and with this survey, we’ll draw attention to the importance of annual skin checks in the fight against melanoma."

The company markets MelaFind, a diagnostic tool approved by the Food and Drug Administration for detecting melanoma at its most curable stage, when it is limited to the outermost layer of the skin.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Valeant buys rights to Eisai’s Targretin

BY Alaric DeArment

WOODCLIFF LAKE, N.J. — Valeant Pharmaceuticals has bought rights to a drug used to treat skin cancer from Eisai, the companies said Thursday.

Valeant has bought the rights to Targretin (bexarotene) capsules and gel from Eisai for $65 million upfront, plus additional payments based on certain milestones. Under the deal, Eisai has transferred its regulatory approval application to Valeant, which will assume responsibilities for all regulatory obligations associated with the product in the United States. Eisai will retain rights to the drug outside the United States.

The drug is used to treat skin problems arising from a disease called cutaneous T-cell lymphoma, or CTCL, when at least one systemic therapy has not worked.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?